DIEGO ANDRES ADRIANZEN HERRERA M.D.
Prescription History 1114367463
Internal Medicine - Hematology & Oncology in Burlington, VT

NPI Status: Active since July 01, 2013

Contact Information

111 COLCHESTER AVE
BURLINGTON, VT
ZIP 05401
Phone: (802) 847-0000

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DIEGO ANDRES ADRIANZEN HERRERA M.D., an active Hematology & Oncology specialist practicing in Burlington, VT. Our medical registry currently tracks 23 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 748 documented patient claims. Among these therapy options, the most frequently utilized medication is Acyclovir, which accounts for 171 claims alone.


Acyclovir

Generic Formulation: AcyclovirSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 171
30-Day Fills 225.1
Days Supply 6,688
VT State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills38.1
Peer Average Days Supply1,013
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 557.7% higher than the standard regional baseline profile for VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,923.93 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.10

State Avg Cost Per Claim

$22.84

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.

Therapeutic Applications

Acyclovir is used to treat infections caused by certain types of viruses. It treats cold sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster), and chickenpox. This medication is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, acyclovir is used to help reduce the number of future episodes. Acyclovir is an antiviral drug. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Acyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal. In addition, in people with a weakened immune system, acyclovir can decrease the risk of the virus spreading to other parts of the body and causing serious infections.

Calquence

Generic Formulation: Acalabrutinib MaleateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 570
VT State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills23.0
Peer Average Days Supply681
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $298,204.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,694.96

State Avg Cost Per Claim

$13,730.11

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as mantle cell lymphoma, small lymphocytic lymphoma - SLL, chronic lymphocytic leukemia - CLL). Acalabrutinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.

Dexamethasone

Generic Formulation: DexamethasoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 161
VT State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills27.5
Peer Average Days Supply497
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $198.92 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.58

State Avg Cost Per Claim

$20.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory 9-fluoro-glucocorticoid.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Eliquis

Generic Formulation: ApixabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 68
30-Day Fills 74.2
Days Supply 2,187
VT State Average Benchmarks
Peer Average Claims67.0
Peer Average 30-Day Fills118.2
Peer Average Days Supply3,331
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $44,898.43 across this reporting matrix range.

Provider Avg Cost Per Claim

$660.27

State Avg Cost Per Claim

$899.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Fluconazole

Generic Formulation: FluconazoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 27
30-Day Fills 27.0
Days Supply 664
VT State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills19.0
Peer Average Days Supply227
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 58.8% higher than the standard regional baseline profile for VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,054.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$39.07

State Avg Cost Per Claim

$14.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.

Therapeutic Applications

Fluconazole is used to treat vaginal yeast infections. It works by stopping the growth of common types of vaginal yeast (fungus). This medication belongs to a class of drugs called azole antifungals.

Gabapentin

Generic Formulation: GabapentinSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 16
30-Day Fills 22.0
Days Supply 621
VT State Average Benchmarks
Peer Average Claims70.0
Peer Average 30-Day Fills116.6
Peer Average Days Supply3,352
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 77.1% less volume than the regional standard for practitioners inside VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $153.69 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.61

State Avg Cost Per Claim

$25.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Hydromorphone Hcl

Generic Formulation: Hydromorphone HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 311
VT State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.3
Peer Average Days Supply431
Conservative Utilization

This provider writes prescriptions for this formulation 45.8% less frequently than the standard regional baseline metric for practitioners inside VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $124.39 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.57

State Avg Cost Per Claim

$24.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An opioid analgesic made from MORPHINE and used mainly as an analgesic. It has a shorter duration of action than morphine.

Therapeutic Applications

This medication is used to help relieve moderate to severe pain. Hydromorphone belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 29
30-Day Fills 48.6
Days Supply 1,414
VT State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills61.2
Peer Average Days Supply1,785
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $941.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$32.48

State Avg Cost Per Claim

$35.24

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Imatinib Mesylate

Generic Formulation: Imatinib MesylateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 42
30-Day Fills 42.0
Days Supply 1,260
VT State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills18.5
Peer Average Days Supply556
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 133.3% higher than the standard regional baseline profile for VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $118,621.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,824.32

State Avg Cost Per Claim

$1,848.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome).

Jakafi

Generic Formulation: Ruxolitinib PhosphateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 33
30-Day Fills 33.0
Days Supply 990
VT State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills28.3
Peer Average Days Supply845
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $556,709.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$16,870.00

State Avg Cost Per Claim

$14,231.73

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bone marrow disorders (myelofibrosis, polycythemia vera). It works by blocking your body from producing substances called growth factors. Growth factors cause cells to grow and divide, and cause the blood cell and spleen problems found in these disorders. Ruxolitinib belongs to a class of drugs known as kinase inhibitors. Though not a cure for these disorders, ruxolitinib may help with some of the symptoms, including abdominal discomfort, pain under left ribs, early feelings of fullness from meals, night sweats, itching, and bone/muscle pain. Ruxolitinib is also used to treat a certain problem that may occur after certain stem cell or bone marrow transplants (graft versus host disease). It works by weakening your body's defense system (immune system).

Lenalidomide

Generic Formulation: LenalidomideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 532
VT State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.5
Peer Average Days Supply483
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $279,282.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,699.05

State Avg Cost Per Claim

$15,407.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Levofloxacin

Generic Formulation: LevofloxacinSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 36
30-Day Fills 36.0
Days Supply 1,013
VT State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills19.6
Peer Average Days Supply195
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 89.5% higher than the standard regional baseline profile for VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $481.03 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.36

State Avg Cost Per Claim

$10.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The L-isomer of Ofloxacin.

Therapeutic Applications

This medication is used to treat a variety of bacterial infections. Levofloxacin belongs to a class of drugs known as quinolone antibiotics. It works by stopping the growth of bacteria. Levofloxacin injection is used if you cannot take the medication by mouth. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Lorazepam

Generic Formulation: LorazepamSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 242
VT State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills50.5
Peer Average Days Supply1,233
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 71.7% less volume than the regional standard for practitioners inside VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $29.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$2.26

State Avg Cost Per Claim

$7.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.

Therapeutic Applications

This medication is used to treat serious seizures that do not stop (status epilepticus). It is also used before surgeries or procedures to cause drowsiness, decrease anxiety, and cause forgetfulness about the procedure or surgery. Lorazepam belongs to a class of medications called benzodiazepines, which produce a calming effect on the brain and nerves (central nervous system). It is thought to work by increasing the effect of a certain natural chemical (GABA) in the brain.

Methocarbamol

Generic Formulation: MethocarbamolSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 344
VT State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills22.9
Peer Average Days Supply448
Conservative Utilization

This provider writes prescriptions for this formulation 42.9% less frequently than the standard regional baseline metric for practitioners inside VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $195.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.30

State Avg Cost Per Claim

$16.53

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206)

Therapeutic Applications

Methocarbamol is used to treat muscle spasms/pain. It is usually used along with rest, physical therapy, and other treatment. It works by helping to relax the muscles.

Morphine Sulfate Er

Generic Formulation: Morphine SulfateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 33
30-Day Fills 33.0
Days Supply 759
VT State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills25.7
Peer Average Days Supply691
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 32.0% more claims than the standard regional baseline profile for VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $677.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$20.53

State Avg Cost Per Claim

$50.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle.

Therapeutic Applications

This medication is used to treat severe pain. Morphine belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Ondansetron Odt

Generic Formulation: OndansetronSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 292
VT State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.6
Peer Average Days Supply245
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $622.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$31.15

State Avg Cost Per Claim

$25.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. Ondansetron works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Pomalyst

Generic Formulation: PomalidomideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 644
VT State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills29.3
Peer Average Days Supply819
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $533,561.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$23,198.32

State Avg Cost Per Claim

$21,250.34

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Pomalidomide is used to treat certain types of cancers (such as multiple myeloma, Kaposi sarcoma). It works by slowing or stopping the growth of cancer cells.

Potassium Chloride

Generic Formulation: Potassium ChlorideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 600
VT State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills71.4
Peer Average Days Supply2,028
Conservative Utilization

This provider writes prescriptions for this formulation 47.4% less frequently than the standard regional baseline metric for practitioners inside VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $657.39 across this reporting matrix range.

Provider Avg Cost Per Claim

$32.87

State Avg Cost Per Claim

$38.22

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.

Therapeutic Applications

This medication is a mineral supplement used to treat or prevent low amounts of potassium in the blood. A normal level of potassium in the blood is important. Potassium helps your cells, kidneys, heart, muscles, and nerves work properly. Most people get enough potassium by eating a well-balanced diet. Some conditions that can lower your body's potassium level include severe prolonged diarrhea and vomiting, hormone problems such as hyperaldosteronism, or treatment with water pills/diuretics.

Prednisone

Generic Formulation: PrednisoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 187
VT State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills44.6
Peer Average Days Supply828
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 57.1% less volume than the regional standard for practitioners inside VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $38.71 across this reporting matrix range.

Provider Avg Cost Per Claim

$2.58

State Avg Cost Per Claim

$7.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Prochlorperazine Maleate

Generic Formulation: Prochlorperazine MaleateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 212
VT State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills27.3
Peer Average Days Supply288
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.8% less volume than the regional standard for practitioners inside VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $352.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$29.34

State Avg Cost Per Claim

$15.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)

Therapeutic Applications

This medication is used to treat severe nausea and vomiting from certain causes (for example, after surgery or cancer treatment). Prochlorperazine belongs to a class of drugs known as phenothiazines. This medication is not recommended for use in children younger than 2 years or in children going through surgery.

Revlimid

Generic Formulation: LenalidomideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 35
30-Day Fills 35.0
Days Supply 980
VT State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills50.8
Peer Average Days Supply1,403
Conservative Utilization

This provider writes prescriptions for this formulation 30.0% less frequently than the standard regional baseline metric for practitioners inside VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $692,180.09 across this reporting matrix range.

Provider Avg Cost Per Claim

$19,776.57

State Avg Cost Per Claim

$18,798.48

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 22
30-Day Fills 27.8
Days Supply 800
VT State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills24.7
Peer Average Days Supply360
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $77.16 across this reporting matrix range.

Provider Avg Cost Per Claim

$3.51

State Avg Cost Per Claim

$6.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Venclexta

Generic Formulation: VenetoclaxSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 58
30-Day Fills 58.3
Days Supply 1,536
VT State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.0
Peer Average Days Supply632
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 163.6% higher than the standard regional baseline profile for VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $422,486.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$7,284.26

State Avg Cost Per Claim

$10,149.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of cancer (chronic lymphocytic leukemia-CLL, small lymphocytic lymphoma-SLL, acute myeloid leukemia-AML). Venetoclax is a drug that works by helping to slow or stop the growth of cancer cells.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DIEGO ANDRES ADRIANZEN HERRERA M.D. provides transparency into local medical care patterns within Burlington, VT.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.